



Erratum: A Phase 2 Multi-center, Open-label, Switch-over Trial to Evaluate the Safety and Efficacy of Abcertin® in Patients with Type 1 Gaucher Disease

Jin-Ho Choi, Beom Hee Lee, Jung Min Ko, Young Bae Sohn, Jin-Sung Lee, Gu-Hwan Kim, Sun Hee Heo, June-Young Park, Yoo-Mi Kim, Ja-Hye Kim, and Han-Wook Yoo

To the Editor:

The authors want to clarify the definition of “biosimilar” based on “Regulatory expectations and risk assessment for biotherapeutic products. World Health Organization 2014. available from http://www.who.int/biologicals/WHO_Risk_Assessment_for_Biotherapeutics_1st_PC_24_Jan_2014.pdf”

In this article (*J Korean Med Sci* 2015;30:378-384), as Abcertin® does not meet the exact definition of biosimilar, the authors would like to delete the phrases “a biosimilar of imiglucerase” in Page 379 and “a new biosimilar to imiglucerase” in Page 382.

Thank you.

Sincerely yours,
Yoo HW

Address for Correspondence:

Han-Wook Yoo, MD

Department of Pediatrics, Asan Medical Center Children's Hospital, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 138-736, Korea
Tel.: +82.2 3010 3374, Fax: +82.2 473 3725, E-mail: hwyoo@amc.seoul.kr